Changes between Version 3 and Version 4 of Research/LhARA/Communication/Conferences/2027/ALPA-abstract-rBio


Ignore:
Timestamp:
Nov 9, 2026, 4:49:55 PM (24 hours ago)
Author:
longkr
Comment:

--

Legend:

Unmodified
Added
Removed
Modified

  • Research/LhARA/Communication/Conferences/2027/ALPA-abstract-rBio

    v3 v4  
    55
    66== Technical ==
    7 The Laser-hybrid Accelerator for Radiobiological Applications (LhARA) is a proposed facility designed to deliver laser-driven proton and ion beams for radiobiological research and, ultimately, radiotherapy. LhARA’s scientific programme requires systematic comparison of biological responses across laser-driven ions, cyclotron ions, and X-rays. As a proof-of-principle step toward this goal, the PoPLaR (Proof-of-Principle LhARA Radiobiology) initiative has implemented a laser-driven proton beamline at the SCAPA facility, University of Strathclyde.
     7The Laser-hybrid Accelerator for Radiobiological Applications (LhARA) is a facility proposed to deliver laser-driven proton and ion beams for radiobiological research, thereby proving the feasibility of technologies that could provide transformative capability for radiotherapy. The LhARA collaboration’s scientific programme requires systematic comparison of biological responses across laser-driven ions, cyclotron ions, and X-rays. As a proof-of-principle step toward this goal, the PoPLaR (Proof-of-Principle LhARA Radiobiology) initiative has implemented a laser-driven proton beamline at the SCAPA facility, University of Strathclyde.
    88
    99The PoPLaR beamline, designed, simulated, and optimised using linear optics, transports protons produced via Target Normal Sheath Acceleration (TNSA) through a permanent magnet quadrupole doublet operating at 150 T/m. A copper scatterer selected through Bayesian optimisation delivers a uniform dose field across a bespoke 2.7 cm² cell dish. In Phase 1, beam characterisation was performed using radiochromic film, with proton energies up to 11-12 MeV measured at the target. In Phase 2, the first in-vitro irradiations of biological samples using laser-driven protons were carried out in November 2025. A mean dose of 0.57 Gy per shot was delivered, with a beam uniformity coefficient of variation of 13.9%, reducible to 8.4% through scatterer repositioning. Cells were irradiated at three dose levels targeting 1, 2, and 4 Gy.